Key result
This review evaluates therapeutic strategies and new pharmacological developments for cardiac remodelling, challenging current opinions on hypertrophy, hormones, and inotropic interventions.
This review outlines emerging pharmacological targets for cardiac remodeling, challenging conventional views on hypertrophy and inotropic interventions.
No takes yet. Share an insight, caveat, or question.
Challenges conventional views on hypertrophy and inotropes; leaves open whether emerging targets warrant randomized trials.
Bernard Swynghedauw (2002) conducted a review in Cardiac remodelling and heart failure. Pharmacological targets for myocardial remodelling was evaluated. This review evaluates therapeutic strategies and new pharmacological developments for cardiac remodelling, challenging current opinions on hypertrophy, hormones, and inotropic interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: